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http://dx.doi.org/10.1016/j.jmii.2013Background: The emergence of imipenem-nonsusceptible (INS) Acinetobacter baumannii com-
plex has had a great impact on healthcare systems worldwide. Understanding the risk factors
related to INS infection is useful for infection control. The risk factors for INS A. baumannii
have been well documented; however, the risk factors related to INS Acinetobacter nosoco-
mialis infection lack documentation. The purpose of this study was to identify the risk factors
associated with INS A. nosocomialis bacteremia.
Methods: This retrospective 9-year study included 329 adults with A. nosocomialis bacteremia
in a tertiary medical center in Taiwan. Acinetobacter nosocomialis was identified using a
multiplex polymerase chain reaction method and sequence analysis of a 16Se23S intergenic
spacer.
Results: Among 329 patients with A. nosocomialis bacteremia, 67 had INS isolates (20.4%). Pa-
tients with INS isolates tended to have a more severe form of the diseases [with ICU admission
and a higher APACHE (Acute Physiology and Chronic Health Evaluation) II score], specific under-
lying diseases (associated with chronic lung diseases and end-stage renal diseases, but less
commonly alcoholism and chemotherapy), multiple invasive procedures, pneumonia as anfectious Diseases, Taipei Veterans General Hospital, No. 201, Section 2, Shih-Pai Road, Taipei 112,
il.com (S.-C. Kuo).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
.02.002
312 L. Huang et al.primary focus of infection, and prior antimicrobial use (sulbactam, antipseudomonal penicil-
lins, aminoglycosides, and carbapenems). Multivariable analysis showed that ICU admission,
chronic lung diseases, arterial line catheterization, total parenteral nutrition, and prior use
of carbapenems were independent risk factors; prior use of carbapenems was found to be
the most influential (odds ratio 6.36, 95% confidence interval 2.00e20.21; p Z 0.002).
Conclusion: To our knowledge, this is the first study describing the risk factors associated with
INS A. nosocomialis bacteremia. Regulated antibiotic control policy, especially for carbapenem,
and infection control measures targeting patients hospitalized in ICU, with chronic lung diseases
and multiple invasive procedures, may be helpful in reducing INS A. nosocomialis infection.
Copyright ª 2013, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Nosocomial infections have become a serious problem
worldwide in recent years. One of the nosocomial pathogens
is Acinetobacter baumannii complex (ABC), which frequently
causes outbreaks of infection with high mortality in hospi-
talized patients.1With thewidespreaduse of broad-spectrum
antibiotics and the increasing number of immunocompro-
mised patients, we are now facing the emergence of drug-
resistant ABC worldwide.2 Currently, most ABCs are highly
resistant tomanyof thecommonlyusedantibioticsbecauseof
both intrinsic and acquired mechanisms.3,4 In Europe, the
rate of resistance to carbapenems has been reported to be
27%,5 whereas the SENTRY Surveillance Program found that it
was 42.3% in the Asia-Pacific Rim nations.6 In Taiwan, ac-
cording to the annual report of the Taiwan Nosocomial In-
fectionsSurveillanceSystem, the resistance rate to imipenem
had increased to 66.8% in 2010.7 Studies show that antibiotic
resistance significantlyprolongs thedurationof intensivecare
unit (ICU) stays and hospitalization,8,9 leading to increased
hospitalization costs. In addition, patients with resistant ABC
infection have a higher mortality rate than those infected
with bacterial strains susceptible to antibiotics.8,10,11
The effective control of drug-resistant ABC outbreaks is,
therefore, an important issue requiring knowledge of the
infected population so that the dynamics of the spread of
endemic and epidemic strains can be investigated and appro-
priate control measures can be introduced in a timely
manner.12 Numerous clinical studies on the risk factors for
imipenem-nonsusceptible (INS) ABC infections, including
bacteremia, have been published.13,14 However, ABC com-
prises not only A. baumannii, but also Acinetobacter nosoco-
mialis and Acinetobacter pittii, which can only be
differentiated by molecular methods.15,16 Information con-
cerning the risk factors for INS A. nosocomialis infection is
absent.Therefore, thepurposeof this studywas to identify the
risk factors associated with INS A. nosocomialis bacteremia.Materials and methods
Study population
This retrospective study was conducted between 2000 and
2008 in Taipei Veterans General Hospital, a 2900-bed tertiary
caremedical center in Taiwan. All adults withA. nosocomialis
bacteremia and concurrent symptomsand signs of sepsiswereincluded. Patientswhowere less than 18 years of age orwhose
medical records were not complete were excluded. The
medical records were reviewed and recorded on a standard
form. Demographic data, disease severity represented by the
Acute Physiology and Chronic Health Evaluation (APACHE) II
score, comorbidities, invasive procedures, antimicrobial
agents administered within 1 month prior to the onset of
bacteremia, and infection foci were recorded for analysis.
Definitions
Chronic lungdiseases includedchronic obstructivepulmonary
diseases, tuberculosis, and asthma. Chronic kidney disease
was defined as a glomerular filtration rate (GFR) < 60 mL/
min/1.73m2, whereas end-stage renal diseasewas defined as
a GFR < 15 mL/min/1.73 m2 or receipt of permanent renal
replacement therapy for more than 3 months. Neutropenia
was defined as an absolute neutrophil count<500 cells/mm3.
Immunosuppressant therapy included treatment for
neoplastic diseases and organ transplantation, as well as the
use of corticosteroids (equivalent to more than 10 mg of
prednisolone daily for 5 days) within 4 weeks of the onset of
bacteremia. Long-term intravenous access included Hickman
catheters, port-A-catheters, and other permanent catheters.
The origin of the bacteremia was defined as previously sug-
gested.17 This study was approved by the institutional review
board of Taipei Veterans General Hospital.
Genomic species identification and antimicrobial
susceptibility testing
ABC was phenotypically identified by the 32 GN system
(bioMe´rieux, Marcy l’Etoile, France). The bacteria were
stored at 70C in trypticase cystine agar (Difco Labora-
tories, Le Pont de Claix, France) supplemented with 15%
glycerol before use. Amultiplex polymerase chain reaction15
was used to identify A. baumannii. The non-baumannii Aci-
netobacter species were identified by amplification and
sequence analysis of the 16Se23S rRNA intergenic spacer
using universal primers.16 The susceptibility and non-
susceptibility of imipenem and other antimicrobial agents
were determined by agar dilution methods. The interpreta-
tion was performed according to the guidelines of the Clin-
ical and Laboratory Standards Institute.18 For imipenem, a
minimum inhibitory concentration (MIC)  4 mg/L was
considered to reflect susceptibility, whereas anMIC> 4mg/L
was considered to show a nonsusceptible organism.
Table 1 Demographic data and underlying diseases of patients with imipenem-nonsusceptible (INS) and imipenem-susceptible
(IS) Acinetobacter nosocomialis bacteremia
Characteristics INS isolates (n Z 67) IS isolates (n Z 262) p
Age, median 76 (64e81) 72 (57e79) 0.132
Sex, male 48 (71.6) 179 (68.3) 0.600
Intensive care unit admission 58 (86.6) 121 (46.2) <0.001
APACHE II score 26 (19e32) 18 (14e25) <0.001
Concurrent infections 26 (38.8) 82 (31.3) 0.243
Polymicrobial bacteremia 16 (23.9) 45 (17.2) 0.208
Days of hospitalization prior to bacteremia, median 23 (11e43) 15 (9e26) 0.001
Underlying conditions
Major operations 32 (47.8) 94 (35.9) 0.074
Hypertension 25 (37.3) 73 (27.9) 0.131
Type 2 diabetes mellitus 21 (31.3) 60 (22.9) 0.152
Chronic lung diseases 20 (29.9) 36 (13.7) 0.002
Solid tumor 20 (29.9) 108 (41.2) 0.088
Cerebrovascular diseases 17 (25.4) 49 (18.7) 0.224
Steroid use 14 (20.9) 56 (21.4) 0.932
Chronic kidney diseases 12 (17.9) 45 (17.2) 0.887
Congestive heart failure 11 (16.4) 26 (9.9) 0.133
Coronary artery diseases 11 (16.4) 45 (17.2) 0.883
Shock during bacteremia 10 (14.9) 25 (9.5) 0.202
Smoking 9 (13.4) 47 (17.9) 0.381
End-stage renal disease 8 (11.9) 10 (3.8) 0.015
Autoimmune diseases 4 (6.0) 15 (5.7) >0.99
Chemotherapy 3 (4.5) 47 (17.9) 0.006
Use of immunosuppressants 2 (3.0) 11 (4.2) >0.99
Liver cirrhosis 2 (3.0) 17 (6.5) 0.384
Peripheral arterial occlusive disease 2 (3.0) 4 (1.5) 0.606
Trauma 2 (3.0) 12 (4.6) 0.743
Aortic dissection 1 (1.5) 1 (0.4) 0.297
Burns 1 (1.5) 1 (0.4) 0.297
Hematologic malignancies 1 (1.5) 17 (6.5) 0.138
Neutropenia 1 (1.5) 7 (2.7) >0.99
Alcoholism 0 (0) 29 (11.1) 0.004
Radiotherapy 0 (0) 2 (0.8) >0.99
Data represent the median value (interquartile range) for continuous variables and the number of cases (%) for categorical variables.
APACHE II Z Acute Physiology and Chronic Health Evaluation II.
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All statistical analyses were performed using SPSS software
(version 18.00; SPSS, Chicago, IL, USA). A value of p <0.05
was considered to be statistically significant. Fisher’s exact
test or the Chi-square test was used to compare categorical
variables, whereas the Student t test or ManneWhitney U
test was used to compare the continuous ones. A logistic
regression model was used to determine the independent
risk factors associated with INS A. nosocomialis bacteremia.
All variables with statistical significance in univariable an-
alyses were entered into multivariable analyses to assess
their association with imipenem nonsusceptibility.Results
Among 329 patients with A. nosocomialis bacteremia, 67
(20.4%) patients had INS isolates and the remaining 262
(79.6%) patients had imipenem-susceptible (IS) isolates.Demographic data and the underlying diseases of patients
with INS and IS A. nosocomialis are shown in Table 1.
Compared with patients with IS A. nosocomialis, those who
had INS isolates were admitted to ICU more often (86.6% vs.
46.2%; p < 0.001), had higher APACHE II scores (26 vs. 18;
p < 0.001), had a longer duration of hospitalization prior to
the onset of bacteremia (23 vs. 15 days; p < 0.001), had
more chronic lung diseases (29.9% vs. 13.7%; pZ 0.002), and
suffered from end stage renal disease more commonly
(11.9% vs. 3.8%; p Z 0.015). In contrast, patients with INS
isolates were less likely to have a history of chemotherapy or
alcoholism (4.5% vs. 17.9%, p Z 0.006, and 0.0% vs. 11.1%,
pZ 0.004, for chemotherapy and alcoholism, respectively).
With respect to previous invasive procedures (Table 2),
INS isolates were more commonly recovered from patients
who had undergone multiple invasive procedures (5 vs. 1;
p < 0.001) such as use of a nasogastric tube (82.1% vs.
43.1%; p < 0.001), foley catheterization (77.6% vs. 42.4%;
p < 0.001), central venous catheterization (76.1% vs. 38.2%;
p < 0.001), mechanical ventilation (74.6% vs. 32.4%;
Table 2 Previous use of invasive procedures in patients with imipenem-nonsusceptible (INS) and imipenem-susceptible (IS)
Acinetobacter nosocomialis bacteremia
Characteristics INS isolates (n Z 67) IS isolates (n Z 262) p
Total number of invasive procedures, median 5 (3e6) 1 (0e4) <0.001
Nasogastric tube 55 (82.1) 113 (43.1) <0.001
Foley catheterization 52 (77.6) 111 (42.4) <0.001
Central venous catheter 51 (76.1) 100 (38.2) <0.001
Mechanical ventilation 50 (74.6) 85 (32.4) <0.001
Arterial line catheter 33 (49.3) 35 (13.4) <0.001
Pulmonary arterial catheter 15 (22.4) 28 (10.7) 0.011
Tracheostomy 12 (17.9) 23 (8.8) 0.031
Total parenteral nutrition 10 (14.9) 10 (3.8) 0.002
Abdominal drainage 9 (13.4) 26 (9.9) 0.406
Thoracic drainage 9 (13.4) 16 (6.1) 0.043
Extraventricular drainage 3 (4.5) 7 (2.7) 0.431
Long-term intravenous access 2 (3.0) 14 (5.3) 0.541
Arteriovenous fistula or shunt 1 (1.5) 3 (1.1) >0.99
Data represent the median value (interquartile range) for continuous variables and the number of cases (%) for categorical variables.
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p < 0.001), a pulmonary arterial line (22.4% vs. 10.7%;
pZ 0.011), tracheostomy (17.9% vs. 8.8%; pZ 0.031), total
parenteral nutrition (14.9% vs. 3.8%; p Z 0.002), and
thoracic drainage (13.4% vs. 6.1%; p Z 0.043).
The difference in antimicrobial susceptibility between
INS and IS isolates is given in Table 3. Compared to IS iso-
lates, INS isolates were more resistant to piperacillin/
tazobactam, ampicillin/sulbactam, colistin, amikacin and
gentamicin. The antimicrobial agents that had high activity
against INS isolates were ciprofloxacin (92.5%), ceftazidime
(77.6%), cefepime (80.6%), and sulfamethoxazole/trimeth-
oprim (76.1%). Patients with INS isolates more frequently
received antibiotics prior to the onset of bacteremia (77.6%
vs. 51.1%, p < 0.001) than those with IS isolates. Further
analysis, as shown in Table 4, revealed that the use of
antipseudomonal penicillins, aminoglycosides, carbape-
nems, and sulbactam was associated with the recovery of
INS isolates (all p < 0.05). Pneumonia was the most com-
mon source of A. nosocomialis bacteremia in both the IS
and INS groups (Table 4). Patients with INS isolates tended
to have pneumonia as a source of infection (71.6% vs.Table 3 The antimicrobial susceptibility of imipenem-nonsus
nosocomialis
Antibiotics INS isolates (n Z
Ceftriaxone 17 (25.4)
Ceftazidime 52 (77.6)
Cefepime 54 (80.6)
Ciprofloxacin 62 (92.5)
Piperacillin/tazobactam 21 (31.3)
Ampicillin/sulbactam 38 (56.7)
Colistin 37 (55.2)
Amikacin 32 (47.8)
Gentamicin 8 (11.9)
Sulfamethoxazole/trimethoprim 51 (76.1)
Data presented as number of cases (%).40.8%; p < 0.001), with the infection less commonly caused
by primary bacteremia (10.4% vs. 29.8%; p Z 0.001),
compared with those with IS isolates.
After multivariable analysis (Table 5), the independent
risk factors for harboring INS isolates included admission to
ICU, chronic lung diseases, previous arterial line catheter-
ization, total parenteral nutrition, and previous use of
carbapenems. Previous use of carbapenems was the most
influential risk factor (odds ratio 6.36, 95% confidence in-
terval 2.00e20.21; p Z 0.002).Discussion
INS ABC has emerged in recent years because of the
increasing number of susceptible patients and the wide-
spread use of broad-spectrum antimicrobials.2 Although
most studies have delineated the risk factors for INS ABC
infections, this is the first study targeting patients with INS
A. nosocomialis bacteremia. Using multivariable analysis,
our study, spanning 9 years and including 329 patients,
revealed the independent risk factors for acquiring INSceptible (INS) and imipenem-susceptible (IS) Acinetobacter
67) IS isolates (n Z 262) p
74 (28.2) 0.752
220 (84.0) 0.297
229 (87.4) 0.216
243 (92.7) 0.842
229 (87.4) <0.001
216 (82.4) <0.001
220 (84.0) <0.001
201 (76.7) <0.001
183 (69.8) <0.001
175 (66.8) 0.186
Table 4 Previous use of antimicrobial agents and infection sources of patients with imipenem-nonsusceptible (INS) and
imipenem-susceptible (IS) Acinetobacter nosocomialis bacteremia
Characteristics INS isolates (n Z 67) IS isolates (n Z 262) p
Previous use of antimicrobial agents
Antipseudomonal penicillins 19 (28.4) 19 (7.3) <0.001
Aminoglycosides 17 (25.4) 34 (13.0) 0.012
Carbapenems 13 (19.4) 6 (2.3) <0.001
Antipseudomonal cephalosporins 9 (13.4) 33 (12.6) 0.855
Sulbactam or ampicillin/sulbactam 5 (7.5) 5 (1.9) 0.033
Fluoroquinolones 4 (6.0) 11 (4.2) 0.517
Infection sources
Pneumonia 48 (71.6) 107 (40.8) <0.001
Primary bacteremia 7 (10.4) 78 (29.8) 0.001
Catheter-related infections 7 (10.4) 31 (11.8) 0.752
Intra-abdominal infections 3 (4.5) 16 (6.1) 0.774
Skin and soft tissue infections 1 (1.5) 14 (5.3) 0.322
Urinary tract infections 1 (1.5) 13 (5.0) 0.316
Data presented as number of cases (%).
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ease, previous arterial line catheterization, total paren-
teral nutrition, and, most importantly, previous use of
carbapenems. In addition, our study revealed that cipro-
floxacin, ceftazidime, cefepime, and sulfamethoxazole/
trimethoprim had the highest susceptibility rate against INS
isolates.
Numerous clinical studies have delineated the risk fac-
tors for INS A. baumannii infections.10,13,14,19,20 Hospital
settings (ICU stay, length of hospital stay prior to infec-
tion),19,21 underlying diseases (chronic lung diseases),22
prior colonization with A. baumannii,11 multiple invasive
procedures (catheterizations, mechanical ventilation),23e25
and prior antibiotic use (especially use of carbape-
nems)10,25,26 have been linked to the presence of INS iso-
lates. However, evidence regarding the risk factors for
infection with INS A. nosocomialis, which is the second
most clinically relevant species, is lacking. The increasing
rate of nonsusceptibility of A. nosocomialis to imipenem27
may pose a threat to infection control against A. bau-
mannii as INS A. nosocomialis could serve as a reservoir of
resistant genes for A. baumannii.28 Understanding risk
factors associated with INS A. nosocomialis bacteremia
helps to guide infection control measures and to reduce theTable 5 Multivariate analyses of risk factors for bacteremia wit
Variables Univariate anal
Odds ratio (95% confidence
interval)
Intensive care unit admission 7.51 (3.57e15.79)
Chronic lung diseases 2.67 (1.42e5.02)
Previous use of arterial line
catheterization
6.30 (3.47e11.43)
Previous use of total parenteral
nutrition
4.42 (1.76e11.13)
Previous use of carbapenems 10.27 (3.74e28.23)transmission of drug-resistant pathogens.12 This study
showed that the independent risk factors for INS A. noso-
comialis were similar to those for INS A. baumannii. Among
them, carbapenem exposure is the most important risk
factor for infection with INS A. baumannii. The risk of
infection with INS isolates was six times higher in those
previously treated with carbapenems, as reported by
studies on INS ABC.10,13,19,26 Moreover, other risk factors
identified in our study, such as ICU stay, multiple invasive
procedures, and chronic lung diseases, were consistent
with those in previous studies on INS ABC,19,21e24 which
implied the roles of susceptible hosts, available access, and
antecedent antimicrobial exposure.
The optimal therapy for INS A. nosocomialis is unknown
because most of the clinical study focused on A. bau-
mannii.3 In addition, the rarity of recovery of A. nosoco-
mialis prohibits a prospective study. Based on the in vitro
susceptibility results in our study, ciprofloxacin, ceftazi-
dime, cefepime, or sulfamethoxazole/trimethoprim may
be the reasonable treatment of choice, which has been also
successfully used for A. baumannii.3,18
As the presence of carbapenemase did not necessarily
lead to resistance to antimicrobial agents other than car-
bapenems,29 the different antimicrograms (Table 3) for INSh imipenem-nonsusceptible (INS) Acinetobacter nosocomialis
ysis Multivariate analysis
p Odds ratio (95% confidence
interval)
p
<0.001 3.85 (1.65e8.96) 0.002
0.002 2.72 (1.27e5.83) 0.010
<0.001 2.31 (1.11e4.81) 0.026
0.002 5.49 (1.65e18.39) 0.006
<0.001 6.36 (2.00e20.21) 0.002
316 L. Huang et al.A. baumannii and INS A. nosocomialis may indicate the
different ways of acquiring resistance mechanisms. Accu-
mulation of resistance gene cassettes or islands by inte-
grons or transposons has been reported repeatedly for INS
A. baumannii but rarely for A. nosocomialis.30 To delineate
the resistance mechanisms toward these antimicrobial
agents, such as alterations in porins, the presence of an
efflux pump31 or other beta-lactamases,29 or point muta-
tions in gyrA or parC,32 is beyond the scope of this study.
Therefore, further studies targeting the resistance mech-
anisms of A. nosocomialis toward antimicrobial agents
other than carbapenems are needed.
This study had some limitations. Its retrospective nature
precluded investigation of the role of previous infections
with INS A. nosocomialis, which needs further study. One
positive feature is that a large number of patients with A.
nosocomialis bacteremia were included in this study. In
addition, the isolation of A. nosocomialis from the blood of
patients with concurrent symptoms and signs of sepsis
reduced the chances of contamination.
In conclusion, compared to patients with IS A. nosoco-
mialis bacteremia, risk factors for INS A. nosocomialis in-
fections included ICU admission, chronic lung diseases,
previous arterial line catheterization, total parenteral
nutrition, and carbapenems. A regulated antibiotic control
policy against carbapenems and infection control measures
targeting patients with these risk factors may be beneficial.
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